We are conscious that as we extend services to an ever increasing number of patients, we need to keep track of the quality of care that we continue to provide. We therefore maintain a database of all the major diseases we treat and subject them to periodic analysis to assess outcome of the care that we provide. We are fortunate to have personnel who can maintain and manage these data and provide us with the kind of outcome data that we need to ensure continuously improving quality of care.
Treatment of many haematological diseases is extremely expensive. Apart from providing major subsidization of costs from our own funds (~35% of our total turnover) towards the care of such patients, we also arrange for external funds to further subsidize their care
Allogeneic Stem Cell Transplantation forThalassemia Major. Hematol Oncol Clin North Am. 2014 Dec;28(6):1187-1200. doi: 10.1016/j.hoc.2014.08.009. Mathews V, Srivastava A, Chandy M. Epub 2014 Sep 22. Review. PubMed PMID: 25459187.